Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Adicet Bio's Total Liabilities for the quarter that ended in Dec. 2023 was $37.12 Mil. Adicet Bio's Total Assets for the quarter that ended in Dec. 2023 was $207.30 Mil.
Therefore, Adicet Bio's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.18.
Adicet Bio Liabilities-to-Assets Historical Data
The historical data trend for Adicet Bio's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Adicet Bio's Liabilities-to-Assets
For the Biotechnology subindustry, Adicet Bio's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio's Liabilities-to-Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Liabilities-to-Assets falls into.
Adicet Bio Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Adicet Bio's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (NAS:ACET) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Adicet Bio Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of Adicet Bio's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACET has been successfully added to your 